Biogen shares plunge after Alzheimer’s drug setback
Biotech giant halts late-stage trials as results disappoint
Shares in Biogen plummeted yesterday after the biotechnology giant said that its experimental Alzheimer’s drug was unlikely to be effective and that it was halting its research, in another setback to efforts to find a therapy for the neurodegenerative ailment.
Shares dropped by ...